Next Science (ASX:NXS) - Outgoing CEO and Managing Director, Judith Mitchell
Outgoing CEO and Managing Director, Judith Mitchell
Source: Next Science
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Next Science (NXS) appoints Harry Thomas Hall IV (I.V.) as its newest Managing Director and Chief Executive Officer
  • I.V. has worked in the global medical device industry, holding a number of roles across product development, global strategic marketing, commercial operations and sales leadership
  • I.V. will commence in the role on July 10, while current CEO Judith Mitchell remains with the company until the end of July to ensure a smooth leadership transition
  • Shares rose 4.72 per cent to 55.5 cents at midday AEST

Next Science (NXS) has appointed Harry Thomas Hall IV (I.V.) as its newest Managing Director and Chief Executive Officer.

I.V. will begin in the role from July 10, on a total fixed remuneration contract of US$450,000 (A$653,000) per annum.

For more than 25 years, I.V. has worked in the global medical device industry, holding a number of roles across product development, global strategic marketing, commercial operations and sales leadership.

He is also the president of Trauma, Extremities, Craniomaxillofacial and Animal Health, responsible for the global portfolio and execution strategy for a US$3.2 billion platform (A$4.64 billion).

“I.V. is a respected leader in the healthcare industry marrying a rare blend of scientific, clinical and commercial skill and experience,” Next Science Chair Professor Mark Compton AM said.

“I.V. has a proven track record in building successful businesses, and just as importantly, a successful organisational culture.”

Mr Compton also thanked outgoing CEO Judith Mitchell for her contribution to the company and its development of XBIO.

“Judith has built a strong presence for Next Science in the US in particular, led the company through its ASX listing and built a team focused on commercial success,” Mr Compton said.

Next Science is now focusing on commercialising its XBIO technology which aim to reduce the impact of biofilm-based infections.

Judith Mitchell will remain with the company until the end of July to aid in a smooth handover.

Shares in NXS rose 4.72 per cent to 55.5 cents at midday AEST.

NXS by the numbers
More From The Market Online

Will copper prices continue to run? A look at how we got here & what experts think

Copper is having a bull run in YTD – that much is clear. So where do…

Aspire Mining secures approval for Ovoot Coking Coal Project road in Mongolia

Aspire Mining (ASX:AKM) has announced the approval of the Detailed Environmental Impact Assessment (DEIA) for the…

Adore CEO steps down as revenues go up

Adore Beauty's chief executive officer is stepping down at the same time that the company's quarterly…